---
title: "BioXcel Therapeutics, Inc. (BTAI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BTAI.US.md"
symbol: "BTAI.US"
name: "BioXcel Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:39:01.936Z"
locales:
  - [en](https://longbridge.com/en/quote/BTAI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BTAI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BTAI.US.md)
---

# BioXcel Therapeutics, Inc. (BTAI.US)

## Company Overview

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.bioxceltherapeutics.com](https://www.bioxceltherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: E (0.80)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 367 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -63.28% |  |
| Net Profit YoY | -88.04% |  |
| P/B Ratio | -0.28 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 29240552.88 |  |
| Revenue | 680000.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 76.98% | A |
| Profit Margin | -11078.53% | E |
| Gross Margin | -37.38% | E |
| Revenue YoY | -63.28% | E |
| Net Profit YoY | -88.04% | E |
| Total Assets YoY | -11.77% | E |
| Net Assets YoY | -17.05% | E |
| Cash Flow Margin | 76.17% | C |
| OCF YoY | -63.28% | E |
| Turnover | 0.02 | E |
| Gearing Ratio | 410.19% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BioXcel Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-63.28%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-88.04%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-0.28",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "29240552.88",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "680000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "76.98%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-11078.53%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-37.38%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-63.28%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-88.04%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-11.77%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-17.05%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "76.17%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-63.28%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "410.19%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.39 | 122/386 | - | - | - |
| PB | -0.28 | 466/386 | - | - | - |
| PS (TTM) | 43.00 | 230/386 | 58.16 | 48.28 | 6.64 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Underweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.08 |
| Highest Target | 38.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BTAI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BTAI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BTAI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BTAI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**